Standard BioTools to Merge with Treeline in $900 Million Cash-Rich Deal
LAB•Standard BioTools will merge with Treeline Biosciences in an all-stock transaction to form a combined company named Treeline Biosciences with over $900 million pro-forma cash to fund operations into 2029. The merged entity’s oncology pipeline includes three Phase 1 programs with data readouts starting in 2027.
1. Merger Structure and Timeline
Standard BioTools and Treeline Biosciences have entered a definitive all-stock merger agreement, creating a single public company renamed Treeline Biosciences. The transaction is expected to close in the second half of 2026, with the combined entity trading on Nasdaq under the symbol TRLN.
2. Strengthened Balance Sheet
At closing, the merged company will hold over $900 million in pro-forma cash, including approximately $450 million net cash contributed by Standard BioTools. This funding is projected to support operations through 2029 and underpins upcoming clinical and discovery efforts.
3. Oncology Pipeline and Clinical Milestones
Treeline’s pipeline features three Phase 1 clinical programs—TLN-121 (BCL6 degrader), TLN-372 (pan-KRAS inhibitor) and TLN-254 (EZH2 inhibitor)—with interim data readouts expected beginning in 2027. A fourth program, TLN-499 (BCL-XL degrader), is slated for Phase 1 entry later in 2026, and three more programs target oncology, neurology and immunology in 2027-2028.
4. Strategic Review of Legacy Units
Treeline will not operate Standard BioTools’s Mass Cytometry and Microfluidics divisions. Standard BioTools is exploring divestiture and other strategic options to maximize value from these assets for existing shareholders.
